Deferasirox: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), PBAC (Australia) and PHARMAC (New Zealand), among others, recommended or restricted deferasirox, while CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 15.9 years separate the first record, 29 Dec 2006 at TLV (Sweden), from the most recent, 23 Nov 2022 at HAS (France).
AWMSG (Wales) changed its position: recommended on 18 Jul 2008, not recommended by 29 Jul 2013.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for deferasirox, 1 submission was never made — an outcome set by the company rather than the assessor.
7 distinct indication wordings are recorded for deferasirox by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 17 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess deferasirox, on 29 Dec 2006; CIPM (Spain) did not open a file until 15 Sep 2020 — an unusually long tail of 13.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 11 years in total.
6 of the 7 agencies here assessed deferasirox more than once, SMC (Scotland) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for deferasirox.
The full ledger for deferasirox reads 10 recommended, 3 restricted, 2 not recommended and 1 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 23 Nov 2022 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| CIPM (Spain) | 15 Sep 2020 | Indicación terapéutica: Deferasirox está indicado para el tratamiento de la sobrecarga férrica crónica debida a transfus… | not financed by the SNS · art. 92 d | source |
| PBAC (Australia) | 2020 | Chronic iron overload | The PBAC recommended the listing of Deferasirox Juno® for patients with chronic iron overl… | source |
| SMC (Scotland) | 12 Jun 2017 | Treatment of chronic iron overload due to frequent blood transfusions (≥7mL/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and … | accepted (restricted) | source |
| AWMSG (Wales) | 14 Feb 2017 | Treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in pat… | outside AWMSG criteria | source |
12 further decisions for deferasirox, across 6 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- sevelamer — same ATC class V03A — Other therapeutic products
- patiromer — same ATC class V03A — Other therapeutic products
- deferiprone — same ATC class V03A — Other therapeutic products
- difelikefalin — same ATC class V03A — Other therapeutic products
- naloxone — same ATC class V03A — Other therapeutic products
- andexanet alfa — same ATC class V03A — Other therapeutic products
Coverage: 17 decisions for deferasirox from 7 agencies, 2006 to 2022. Data to 7 Sep 2026. ATC class V03A — Other therapeutic products. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.